{"drugs":["Agomelatine"],"mono":{"0":{"id":"930346-s-0","title":"Generic Names","mono":"Agomelatine"},"1":{"id":"930346-s-1","title":"Dosing and Indications","sub":[{"id":"930346-s-1-4","title":"Adult Dosing","mono":"<ul><li>agomelatine has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>no dosage taper necessary upon discontinuation<\/li><li>when switching from an SSRI or a serotonin norepinephrine reuptake inhibitor (SNRI), discontinuation symptoms may occur; agomelatine can be started immediately while tapering the SSRI or SNRI<\/li><li><b>Major depressive disorder:<\/b> (74 years or younger) 25 mg ORALLY at bedtime; if no response after 2 weeks, may increase to 50 mg ORALLY at bedtime for at least 6 months duration (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930346-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy in pediatric patients younger than 18 years not established "},{"id":"930346-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment, including cirrhosis or active liver disease, or transaminases exceeding 3 times ULN:<\/b> use is contraindicated<\/li><li><b>geriatric:<\/b> dosage adjustments are not required in patients 74 years or younger; use not recommended in patients 75 years or older<\/li><\/ul>"},{"id":"930346-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Major depressive disorder<br\/>"}]},"3":{"id":"930346-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930346-s-3-9","title":"Contraindications","mono":"<ul><li>Concomitant use of potent CYP1A2 inhibitors<\/li><li>Hepatic impairment (ie, cirrhosis or active liver disease) or transaminase levels greater than 3 times ULN<\/li><li>Hypersensitivity to agomelatine or any component of the product<\/li><\/ul>"},{"id":"930346-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Use not recommended among patients with hereditary galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption, as product contains lactose<\/li><li>Hepatic:<\/li><li>-- Life-threatening and fatal liver injury, liver enzyme elevations greater than 10 times ULN, hepatitis, and jaundice have been reported, generally in the first few months of treatment; monitoring recommended; drug discontinuation may be warranted<\/li><li>-- Use cautiously among patients with hepatic injury risk factors (eg, obesity, nonalcoholic fatty liver disease, diabetes, substantial alcohol intake, concomitant use of hepatotoxic agents)<\/li><li>-- Increases in transaminase levels have been reported; monitoring recommended, especially during dose increases; use is contraindicated if levels are above 3 times ULN<\/li><li>-- Risk of substantially increased drug exposure among patients with chronic mild (Child-Pugh A) or moderate (Child-Pugh B) liver impairment<\/li><li>Psychiatric:<\/li><li>-- Worsening depression, suicidal ideation, and suicidal behavior may occur, especially during the first few weeks of therapy, following dosage changes, and in patients below age 25 or with a history of suicide-related events or ideation prior to therapy; monitoring recommended<\/li><li>-- Use cautiously in patients with a history of bipolar disorder, mania, or hypomania; discontinue use if manic symptoms develop<\/li><li>Renal:<\/li><li>-- Use cautiously in patients with moderate or severe renal impairment<\/li><li>Other:<\/li><li>-- Not recommended for elderly patients with dementia or in patients 75 years or older, as efficacy is not established<\/li><li>-- Not recommended for pediatric patients (ie, under age 18 years) for depression therapy<\/li><li>Concomitant Use:<\/li><li>-- Alcohol use should be avoided<\/li><\/ul>"},{"id":"930346-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930346-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"930346-s-4","title":"Drug Interactions","sub":[{"id":"930346-s-4-13","title":"Contraindicated","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Enoxacin (theoretical)<\/li><li>Fluvoxamine (theoretical)<\/li><\/ul>"},{"id":"930346-s-4-14","title":"Major","mono":"<ul>Pixantrone (theoretical)<\/ul>"}]},"5":{"id":"930346-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Hyperhidrosis (1% to less than 10%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (1% to less than 10%), Constipation (1% to less than 10%), Diarrhea (1% to less than 10%), Nausea (1% to less than 10%), Vomiting (1% to less than 10%)<\/li><li><b>Hepatic:<\/b>Increased liver enzymes (1.4% to 2.5%)<\/li><li><b>Musculoskeletal:<\/b>Backache (1% to less than 10%)<\/li><li><b>Neurologic:<\/b>Dizziness (1% to less than 10%), Headache (1% to less than 10%), Insomnia (1% to less than 10%), Migraine (1% to less than 10%), Somnolence (1% to less than 10%)<\/li><li><b>Psychiatric:<\/b>Anxiety (1% to less than 10%)<\/li><li><b>Other:<\/b>Fatigue (1% to less than 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hepatic:<\/b>Hepatitis (0.01% to less than 0.1%), Jaundice (0.01% to less than 0.1%), Liver failure (0.01% to less than 0.1%)<\/li><li><b>Psychiatric:<\/b>Hallucinations (0.01% to less than 0.1%)<\/li><\/ul>"},"6":{"id":"930346-s-6","title":"Drug Name Info","sub":{"2":{"id":"930346-s-6-19","title":"Class","mono":"Antidepressant<br\/>"},"3":{"id":"930346-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930346-s-7","title":"Mechanism Of Action","mono":"Agomelatine is an antidepressant with melatonergic agonist (MT(1) and MT(2) receptors) and serotonin-2c (5-HT(2c)) antagonist activity. It increases noradrenaline and dopamine release in the frontal cortex, specifically, with no influence on extracellular levels of serotonin.<br\/>"},"8":{"id":"930346-s-8","title":"Pharmacokinetics","sub":[{"id":"930346-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1 to 2 hours<\/li><li>Bioavailability, Oral: low with substantial variability<\/li><li>Effects of food: no change in bioavailability or rate of absorption<\/li><\/ul>"},{"id":"930346-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 95%<\/li><li>Vd: 35 L<\/li><\/ul>"},{"id":"930346-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: rapid via CYP1A2<\/li><li>Demethylated agomelatine, hydroxylated agomelatine: inactive<\/li><li>substrate of CYP1A2<\/li><\/ul>"},{"id":"930346-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 80% changed<\/li><li>Total body clearance: 1100 mL\/min<\/li><\/ul>"},{"id":"930346-s-8-27","title":"Elimination Half Life","mono":"1 to 2 hours <br\/>"}]},"9":{"id":"930346-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>administer with or without food <br\/>"},"10":{"id":"930346-s-10","title":"Monitoring","mono":"<ul><li>Reduction in severity or resolution of depressive symptoms in adults indicates efficacy<\/li><li>Liver function tests at baseline, then periodically at approximately 3, 6 (end of acute phase), 12, and 24 weeks (end of maintenance phase) following treatment initiation or dose increases and thereafter when clinically indicated; for increased serum transaminases during treatment, repeat liver function tests within 48 hours; if increases in serum transaminases exceed 3 times the ULN discontinue treatment immediately and repeat liver function tests until levels return to normal<\/li><li>Clinical worsening of depression, suicidal thinking and behavior (suicidality), or unusual changes in behavior; at treatment initiation, first few months of therapy, and dose increases or decreases, especially in patients with a history of suicidal ideation or behavior<\/li><\/ul>"},"13":{"id":"930346-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness and somnolence.<\/li><li>Drug may cause insomnia, migraine, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, hyperhidrosis, back pain, tiredness, and anxiety.<\/li><li>Advise patient that symptomatic improvement may not be seen for several weeks.<\/li><li>Instruct patient to report worsening depression, suicidal ideation, or unusual changes in behavior (eg, mania), especially at initiation of therapy or with dose changes.<\/li><li>Instruct patient to immediately report signs\/symptoms of liver injury (eg, dark urine, light-colored stools, yellow skin or eyes, pain in the upper right belly, sustained new-onset and unexplained fatigue).<\/li><li>Patient should avoid drinking alcohol while taking this drug.<\/li><\/ul>"}}}